A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas-Reference-Cited by-同舟云学术

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

Published:2010-02-08 Issue:3 Volume:51 Page:447-455
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Weidmann Eckhart,Hess Georg,Chow Kai U.,Krause Stefan W.,Subklewe Marion,Kruse Judith,Weisel Katja C.,Soekler Martin,Kim Soo-Zin,Napieralski Simone,Rech Jürgen,Dreyling Martin,Jäger Elke,Mitrou Paris S.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428190903580402

Reference26 articles.

1. Diagnosis and actual therapy strategies in peripheral T-cell lymphomas: summary of an international meeting

2. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

3. Therapy of Peripheral T/NK Neoplasms

4. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.

5. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Approaches to T-Cell Lymphoma;Journal of Personalized Medicine;2021-05-27

2. Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma;Experimental Hematology & Oncology;2020-11-13

3. Contemporary strategies to improve outcomes for peripheral T-cell lymphoma patients following the failure of first-line therapy;Expert Review of Hematology;2020-06-01

4. New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine–mitoxantrone–cyclophosphamide–alemtuzumab induction followed by alemtuzumab maintenance;Leukemia & Lymphoma;2018-09-20

5. Recent advances in understanding and managing T-cell lymphoma;F1000Research;2017-12-12